AAA

"Netter-1"

177Lu-DOTA0-Tyr3-Octreotate

Pivotal Phase III Study

A new investigational therapy for midgut carcinoid tumor.

A clinical study in patients with midgut carcinoid tumor.

100 patients per arm

first patient enrolled in July 2012

37 EU Sites

Austria, Belgium, France, Germany, Italy, Portugal, Spain, United Kingdom

14 US Sites

Dear Madam / Sir,

a new therapeutic approach is being tested in patients with midgut carcinoid tumor.

This website provides summary information on an international clinical study (NETTER-1 study) involving Nuclear Medicine Centers in Europe and the USA, to verify the efficacy and safety of the investigational therapy (177Lu-DOTA0-Tyr3-Octreotate) in comparison with an already assessed treatment (Octreotide LAR).

Title of the study:

A multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumors.

read more >